Tim Funnell, Ascend executive director
Ascend launches with $130M+ as it looks to build in the AAV space
Ascend Gene & Cell Therapies, a CDMO for AAV-based therapies, has emerged from stealth with $130 million in funding and plans to acquire experienced teams …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
